(Q37960533)

26 August 2017

title

Therapeutic potential of chemokine receptor antagonists for liver disease (English)

1 reference

26 August 2017

Hacer Sahin

1

1 reference

26 August 2017

Marie-Luise Berres

series ordinal

2

1 reference

26 August 2017

Hermann E Wasmuth

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

Expert Review of Clinical Pharmacology

26 August 2017

published in

1 reference

26 August 2017

volume

4

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

503-513

1 reference

Functional role of chemokines in liver disease models

26 August 2017

cites work

1 reference

Chemokines and chemokine receptors: an overview.

21 January 2018

1 reference

Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function

21 January 2018

1 reference

Fine-tuning leukocyte responses: towards a chemokine 'interactome'

21 January 2018

1 reference

Anti-chemokine small molecule drugs: a promising future?

21 January 2018

1 reference

Chemokine receptor antagonists: Part 1.

21 January 2018

1 reference

Chemokine receptor antagonists: part 2.

21 January 2018

1 reference

A T cell-dependent experimental liver injury in mice inducible by concanavalin A

21 January 2018

1 reference

CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis

21 January 2018

1 reference

The CCR5- 32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source

21 January 2018

1 reference

Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice

21 January 2018

1 reference

Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration

21 January 2018

1 reference

Maraviroc: a new CCR5 antagonist

21 January 2018

1 reference

Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment

21 January 2018

1 reference

Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines.

21 January 2018

1 reference

TLR4 enhances TGF-beta signaling and hepatic fibrosis

21 January 2018

1 reference

Blood monocytes consist of two principal subsets with distinct migratory properties

21 January 2018

1 reference

Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes.

21 January 2018

1 reference

CCR2 promotes hepatic fibrosis in mice

21 January 2018

1 reference

Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice

21 January 2018

1 reference

Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy

21 January 2018

1 reference

C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice

21 January 2018

1 reference

Tuning inflammation and immunity by chemokine sequestration: decoys and more

21 January 2018

1 reference

D6 and the atypical chemokine receptor family: novel regulators of immune and inflammatory processes.

21 January 2018

1 reference

Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C.

21 January 2018

1 reference

ELR+-CXC chemokines and their receptors in early metanephric development

21 January 2018

1 reference

Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury

21 January 2018

1 reference

Chemokine expression during hepatic ischemia/reperfusion-induced lung injury in the rat. The role of epithelial neutrophil activating protein

21 January 2018

1 reference

Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.

21 January 2018

1 reference

Hepatocyte signaling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion in mice

21 January 2018

1 reference

CXC chemokine receptor-1 is expressed by hepatocytes and regulates liver recovery after hepatic ischemia/reperfusion injury

21 January 2018

1 reference

MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment

21 January 2018

1 reference

Direct hepatotoxic effect of KC chemokine in the liver without infiltration of neutrophils

21 January 2018

1 reference

The IL-21 receptor augments Th2 effector function and alternative macrophage activation

21 January 2018

1 reference

Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses

21 January 2018

1 reference

Fibrotic disease and the T(H)1/T(H)2 paradigm

21 January 2018

1 reference

An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4

21 January 2018

1 reference

CXCR 3 activation promotes lymphocyte transendothelial migration across human hepatic endothelium under fluid flow

21 January 2018

1 reference

Enhanced T cell transmigration across the murine liver sinusoidal endothelium is mediated by transcytosis and surface presentation of chemokines.

21 January 2018

1 reference

Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans

21 January 2018

1 reference

CXCR3 antagonism impairs the development of donor-reactive, IFN-gamma-producing effectors and prolongs allograft survival

21 January 2018

1 reference

Lack of CXCR3 delays the development of hepatic inflammation but does not impair resistance to Leishmania donovani.

21 January 2018

1 reference

Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes

21 January 2018

1 reference

Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis

21 January 2018

1 reference

Angiogenesis in liver disease

21 January 2018

1 reference

CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation

21 January 2018

1 reference

Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C.

21 January 2018

1 reference

Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Association of pretreatment serum interferon inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C

21 January 2018

1 reference

Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection

21 January 2018

1 reference

Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV.

21 January 2018

1 reference

CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis

21 January 2018

1 reference

CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3.

21 January 2018

1 reference

Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents.

21 January 2018

1 reference

Compound library design for target families

21 January 2018

1 reference

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

21 January 2018

1 reference

Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus

21 January 2018

1 reference

CXCR7 functions as a scavenger for CXCL12 and CXCL11

21 January 2018

1 reference

CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature

21 January 2018

1 reference

Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells

21 January 2018

1 reference

Cholangiocyte secretion of chemokines in experimental biliary atresia

21 January 2018

1 reference

21 January 2018

1 reference

Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice

21 January 2018

1 reference

The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats

21 January 2018

1 reference

Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases

21 January 2018

1 reference

Chemokine receptor antagonists: overcoming developmental hurdles

21 January 2018

1 reference

The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice

21 January 2018

1 reference

The role of chemokines in the recruitment of lymphocytes to the liver

21 January 2018

1 reference

A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B

21 January 2018

1 reference

Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECP.11.24

1 reference

26 August 2017

1 reference